Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), today announced a conditional issuance of up to 5 million ordinary shares under its existing at-the-market equity offering programs (the “ATM”). This brings the aggregate number of ordinary shares that can be sold and issued under the Company’s ATM to 5,662,694 (the “ATM Shares”), which includes 662,694 shares that are still available from the conditional issuance of shares under the ATM decided upon on December 22, 2022.
Pursuant to the existing sales agreement entered into by the Company on December 22, 2022, ATM Shares may be sold from time to time at a sales price per ATM Share equal to prevailing USD market prices of the Nyxoah ordinary share on the Nasdaq Global Market at the time of the sale.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities.
Contacts:
Nyxoah
John Landry, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.30 |
| Daily Change: | 0.10 1.61 |
| Daily Volume: | 49,816 |
| Market Cap: | US$235.810M |
March 26, 2025 March 13, 2025 February 19, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
